- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30441
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
本帖最后由 StephenW 于 2012-2-26 07:51 编辑
Hepatitis B Surface Antigen (HBsAg) Loss in HBeAg+ Patients with Chronic Hepatitis B (CHB) Treated with Tenofovir Disoproxil Fumarate (TDF)
Reported by Jules Levin
22nd Conference of the Asian Pacifi c
Association for the Study of the Liver (APASL)
February 16-19, 2012
Taipei, Taiwan
P Marcellin1, E Heathcote2, M Buti3, Z Krastev4, I M Jacobson5, R A De Man6, G M Dusheiko7, S Zeuzem8, C N Barnes9, L Lou9 1Hopital Beaujon, University of Paris, Clichy, France; 2Toronto Western Hospital, University of Toronto, Toronto, ON, Canada; 3Servicio de Medicina Interna Hepatologia, Hospital General Universitari Vall d'Hebron and Ciberehd, Barcelona, Spain; 4University Hospital St. Ivan Rilsky, Sofi a, Bulgaria; 5Weill Medical College of Cornell University, New York, NY, USA; 6Erasmus MC Universitiy Medial Center , Rotterdam, The Netherlands; 7Royal Free Hospital, London, UK; 8Medizinische Klinik I, Frankfurt, Germany; 9Gilead Sciences, Foster City, CA
Conclusions
· Continued treatment with TDF increased the proportion of both HBeAg(+) and HBeAg(-)patients with reduced HBsAg level
· Loss of HBsAg is nearly always preceded or accompanied by HBeAg seroconversion and frequently heralded by ALT elevations
============================================
This is a very complex paper for me to report here. I urge you to read the report yourself here:http://www.natap.org/2012/APASL/APASL_20.htm
I will present 5 graphs.
富马酸替诺福韦酯(TDF的治疗慢性乙型肝炎(CHB)患者乙型肝炎表面抗原(HBsAg),HBeAg消失)
报告由朱莱
第22届会议的亚洲PacifiÇ
肝脏研究协会(APASL)
2012年2月16-19日
台北,台湾
带够Marcellin1 E Heathcote2,中号Buti3,Z轴Krastev4,即时Jacobson5,类风湿性关节炎德Man6,通用Dusheiko7,下Zeuzem8,Barnes9点数,大号Lou91Hopital Beaujon,巴黎大学,克利希,法国,多伦多大学,多伦多西区医院2Toronto ON,加拿大3Servicio MEDICINA国际Hepatologia,医院一般Universitari瓦尔德希伯伦和Ciberehd,巴塞罗那,西班牙;4University医院圣伊万Rilsky,SOFI A,保加利亚;5Weill康奈尔大学医学院,纽约州,纽约州,美国;6Erasmus MC Universitiy内侧中心,鹿特丹,荷兰;7Royal自由医院,伦敦,英国;8Medizinische Klinik我,法兰克福,德国;9Gilead科学,福斯特城,加利福尼亚
结论
·续与TDF的治疗增加比例的HBeAg阳性(+)和HBeAg( - )患者HBsAg水平下降
·HBsAg消失之前或几乎总是伴随HBeAg血清转换,ALT升高常常预示
这是一个非常复杂的文件
。我请您自己阅读报告.
我会提出5
个图形。
|
附件: 你需要登录才可以下载或查看附件。没有帐号?注册
|